Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;84(6):e101-e104.
doi: 10.1016/j.jinf.2022.04.010. Epub 2022 Apr 7.

Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)

Guillaume Martin-Blondel  1 , Anne-Genevieve Marcelin  2 , Cathia Soulié  2 , Sofia Kaisaridi  3 , Clovis Lusivika-Nzinga  3 , Céline Dorival  3 , Laura Nailler  4 , Anaïs Boston  4 , Cléa Melenotte  5 , Géraldine Gaube  6 , Christophe Choquet  7 , Roland Liblau  8 , Fabrice Carrat  9 , Youri Yordanov  10 ; COCOPREV Study Group
Affiliations

Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)

Guillaume Martin-Blondel et al. J Infect. 2022 Jun.
No abstract available

Keywords: Omicron; SARS-CoV-2; Sotrovimab.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

Fig. 1
Fig. 1
Change in Ct value of gene N in 66 Delta-infected patients treated with Casirivimab/Imdevimab and in 75 Omicron-infected patients treated with Sotrovimab. The p-value for the slope difference is < 0.0001.
See this image and copyright information in PMC

References

    1. Laura S., Jérémie B., Jérôme D., François C., Rosemary D.S., Alain W., et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg Health Eur. 2021;8 doi: 10.1016/j.lanepe.2021.100158. - DOI - PMC - PubMed
    1. Weinreich D.M., Sumathi S., Thomas N., Shazia A., Haitao G., Rafia B., et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385(23):e81. doi: 10.1056/NEJMoa2108163. - DOI - PMC - PubMed
    1. Anil G., Yaneicy G.R., Erick J., Manuel C.C., Jaynier M., Diego R.F., et al. Effect of Sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022 doi: 10.1001/jama.2022.2832. - DOI - PMC - PubMed
    1. Jennifer H., Heidi L.T., Annie G., Paula A., Weihang B., Wayne W., et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022 doi: 10.1056/NEJMoa2118542. null. - DOI - PMC - PubMed
    1. James H., Colin M., Bell Sidney M., John H., Barney P., Charlton C., et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018;34(23):4121–4123. doi: 10.1093/bioinformatics/bty407. - DOI - PMC - PubMed

Publication types